by Angela C. H. McDonald | Sep 11, 2012
You don’t have to follow pharmaceutical industry news to know that this summer has been a disappointing one for Alzheimer’s research. Many major media outlets covered the failure of potential Alzheimer’s drug bapineuzumab (Pfizer/Johnson & Johnson) in Phase II/III...
by Angela C. H. McDonald | Aug 30, 2012
If you tuned into the evening news on Monday night (at least here in Canada), you would have seen my PhD supervisor Janet Rossant, discussing a recent advancement in stem cell differentiation. Amy Wong, post-doctoral fellow in the Rossant lab, created a protocol for...
by Holly Wobma | Aug 22, 2012
With over 34 million people living with HIV, of which only the fortunate have continual access to life-saving anti-retroviral drugs, it comes as no surprise that the recent media announcement of a potential “cure” for HIV went rapidly…well…viral. The excitement...
by Michelle Ly | Jul 31, 2012
Chances are you know someone with autism spectrum disorder, or have, at the very least, been exposed to it in the media. Films like I am Sam, Rain Main, What’s Eating Gilbert Grape and well-publicized stories such as that of Hollywood starlet Jenny McCarthy and her...
by Lisa Willemse | Jun 29, 2012
With contributions from Michael Rudnicki. If you’re following recent announcements in the field, then you may know about the study published this week in Diabetes that details the use of human embryonic stem cells (hESCs) to reverse diabetes type 1 in a mouse...
by Paul Krzyzanowski | May 22, 2012
Many readers may already have heard of Health Canada’s approval of Osiris’ Prochymal, a mesenchymal stem cell treatment for severe cases of pediatric Graft versus Host Disease (GvHD), with plenty of coverage circulating around the web. GvHD is a disease where...
Comments